Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals ...